INTRODUCTION {#sec1-1}
============

Central neurocytomas (CN) are neuronal neoplasms with little aggressive behavior, which were initially described by Hassoun *et al*. in 1982 as an intraventricular tumor exhibiting histological similarities to oligodendrogliomas.\[[@ref6]\] In 2000, the World Health Organization recognized the existence of extraventricular neurocytomas which received their own classification in 2007, although the intraventricular and extraventricular forms have strong cellular similarity and are both considered grade II tumors.\[[@ref19]\] Approximately 0.1--1.0% of central nervous system neoplasms are CN, and approximately 10% of CN are considered extraventricular at presentation,\[[@ref1]\] although there are \<200 cases reported in the literature.\[[@ref15]\] Thus, we report our experience with an extraventricular central nervous system neurocytoma, which occupied the sellar and suprasellar compartments in a young man and review the related literature.

CASE REPORT {#sec1-2}
===========

History {#sec2-1}
-------

A Brazilian 27-year-old man presented with a 4-year history of progressive bilateral vision loss caused by serious keratoconus. A neuro-ophthalmological evaluation revealed near-total left-eye amaurosis and moderate right-eye vision loss. The patient subsequently underwent bilateral corneal transplantation, although his condition progressed to left amaurosis and right temporal hemianopsia during the following 2 months. Thus, he underwent magnetic resonance imaging (MRI), which revealed a 79-cm^3^ bulky solid expansive lesion that involved the sellar and suprasellar compartments. The lesion had well-defined lobulated margins and a heterogeneous appearance without cystic or calcified components. There was no edema in the adjacent brain parenchyma. The imaging also revealed invasion of the sellar floor, lateral displacement of both internal carotid arteries, medial obliteration of the cavernous sinus, and extrinsic compression of the optic chiasm, hypothalamus, and third ventricle \[[Figure 1](#F1){ref-type="fig"}\]. Injection of a paramagnetic agent revealed diffuse and heterogeneous enhancement in the lesion. The preliminary diagnosis was a pituitary adenoma, and endocrinological evaluation revealed complete loss of pituitary function. Thus, the patient was referred to our department for evaluation and treatment.

![Sagittal (left) and coronal (right) results from gadolinium-enhanced T1-weighted magnetic resonance imaging](SNI-10-8-g001){#F1}

Surgery {#sec2-2}
-------

We initially selected the endoscopic endonasal approach, which revealed that the tumor was unexpectedly firm. We then sent a specimen for intraoperative pathological analysis. The results were inconclusive for macroadenoma, and we chose to stop the surgery until we received a conclusive result (approximately 60% of the tumor had been removed at that point). The patient did not experience any postoperative deficits during the 8 days until we received conclusive pathological diagnosis of CN without signs of malignancy. Immunohistochemical analysis revealed positive synaptophysin expression, a Ki-67 index of 0.8%, and negative AE1/AE3 expression \[[Figure 2](#F2){ref-type="fig"}\]. Based on these results, we performed a second surgery through the right cranio-orbital zygomatic approach, which resulted in successful microsurgical total resection of the tumor.

![Histological sections show solid neoplastic cell proliferation, as well as noncohesive monomorphic small cells with round nuclei, fine chromatin, and well-distributed micronucleoli. The cytoplasm is poorly defined and a fine smooth granular vascular network is observed in the absence of necrosis or mitotic figures. Left: Hematoxylin and eosin staining (×400). Right: Immunohistochemical analysis revealed positive synaptophysin expression, a Ki-67 index of 0.8%, and negative AE1/AE3 expression (×400). Color versions are available as an online supplementary resource](SNI-10-8-g002){#F2}

Postoperative course {#sec2-3}
--------------------

The patient was successfully treated for postoperative insipidus diabetes during a 1-week stay in the intensive care unit. He was subsequently discharged at 3 weeks after his admission to our department without any new neurological deficits and with improvement of the right-eye hemianopsia. Computed tomography (CT) at 1 week after the surgery revealed gross total resection of the tumor and mild ventricular dilation, without any manifestations of hypertensive hydrocephalus that required further treatment \[[Figure 3](#F3){ref-type="fig"}\]. Close outpatient follow-up was performed for 18 months, and the endocrinological workup revealed no improvement of pituitary function, although the patient did not experience any motor, sensory, or autonomic deficits. He continues to receive hormone replacement using testosterone, thyroid hormones, cortisol (prednisone), and exogenous vasopressin (desmopressin). The MRI scans from the 4-month and 18-month follow-ups revealed a hyperintense central sellar mass, which was compatible with an autologous fat graft that was used during the surgery to prevent fistula. These scans also revealed sellar contrast enhancement in both approaches, which was probably related to fibrosis \[[Figure 4](#F4){ref-type="fig"}\]. Thus, if any residual tumor was present, it did not grow during the last year of follow-up.

![Gross total resection of the tumor was confirmed based on the sagital (a), coronal (b), and axial results (c) from the postoperative computed tomography](SNI-10-8-g003){#F3}

![Four-month follow-up axial (a) and sagittal results (b) from T1-weighted magnetic resonance imaging revealed a hyperintense sellar mass, which was compatible with an autologous fat graft that was used to prevent nasal fistula. Findings from T1-weighted gadolinium-enhanced magnetic resonance imaging after 4 months (c) and 18 months (d)](SNI-10-8-g004){#F4}

DISCUSSION {#sec1-3}
==========

Intraventricular and extraventricular CN are equally frequent in 20--40-year-old men and women.\[[@ref4][@ref6][@ref15]\] The symptoms of extraventricular CN are generally nonspecific, including headache, dizziness, nausea, vision changes, and symptoms related to focal compression or intracranial hypertension.\[[@ref4][@ref6][@ref7][@ref13][@ref15]\] The most common sites of extraventricular CN are the frontal lobe (30--46%), parietal lobe (11--23%), temporal lobe (13--20%), occipital lobe (2--11%), and cerebellum (6--9%).\[[@ref2][@ref7][@ref11][@ref13][@ref15]\] Other less common locations include the thalamus, corpus callosum, sella, hypothalamus, pineal region, pons, spinal cord, and sphenoid wing.\[[@ref1][@ref4][@ref15][@ref19]\] Extraventricular CN usually appear as large solitary solid formations and may contain cystic components (40--71%), small calcifications (10--46%), or hemorrhagic foci (20--33%),\[[@ref2][@ref7][@ref11][@ref13]\] whereas CT usually reveals discreetly hyperdense solid portions, compared to the gray matter.\[[@ref8][@ref15]\] The preferred diagnostic modality is MRI as extraventricular CN can have discrete iso/hyperintense signals in both the T1- and T2-weighted images, and signs of restricted water diffusion may also be present. An intense and often heterogeneous enhancement is observed when using intravenous contrast agents, although 5--10% of cases do not exhibit enhancement. Spectroscopy reveals elevated levels of choline and reduced levels of N-acetyl-aspartate.\[[@ref5][@ref8][@ref11][@ref13][@ref14][@ref15][@ref19]\]

The CN lesions can be grade III malignant variants (20--27%), which occur more often in older patients and typically exhibit greater infiltrative behavior, metastatic behavior, and unresectability. These lesions also frequently exhibit atypical cells, marked mitosis, vascular proliferation, necrosis, an MIB1 index of \>2%, and a Ki-67 index of \>2%.\[[@ref1][@ref2][@ref5][@ref7][@ref8][@ref9][@ref11][@ref13][@ref15]\] The treatment of choice for extraventricular CN is total tumor excision, with adjuvant radiotherapy in cases of incomplete or questionable resection. However, there is lack of evidence regarding the ability of adjuvant radiotherapy to prevent recurrence or mortality in these cases.\[[@ref2][@ref5][@ref7][@ref9][@ref11][@ref13][@ref15]\] The typical recurrence rates are 28% for intraventricular CN and 36% for extraventricular CN, with combined mortality rates of 4--6%. However, the atypical variants of intraventricular and extraventricular CN have a two-fold higher rate of unresectability, compared to typical CN, with mortality rates of 20--30% for intraventricular CN and 44% for extraventricular CN.\[[@ref2][@ref5][@ref7][@ref9][@ref15]\]

Sellar and suprasellar extraventricular CN are extremely rare, and only 12 reported cases\[[@ref4][@ref5][@ref10][@ref11][@ref12][@ref14][@ref16][@ref17][@ref18][@ref19]\] were identified during our review of the PubMed and Bireme databases using the following keywords: neurocytoma, central, extraventricular, sellar, suprasellar, pituitary, and hypophysis. The clinical, radiological, pathological, and treatment features of these cases are shown in [Table 1](#T1){ref-type="table"}. The overall age range was 23--64 years, with a higher incidence at the ages of 40--60 years (mean: 49.75 years, median: 50 years), although no sex-specific tendency was observed. Reduced visual acuity was the original complaint in 91.7% of the cases (the symptoms at presentation were not described in one case), with bitemporal or asymmetrical hemianopsia. Half of the reported cases had an interval of 2--12 months between their symptom development and diagnosis, although only six reports described the patient\'s hormonal status and only 66% of those patients had a slight increase in prolactin levels.

###### 

Clinical, radiological, pathological, and treatment features of the 12 reported cases

                                                  Yang GF *et al*. (2009)   Chen H *et al*. (2011)   Yuen Wang Y *et al*. (2012)                   Kaimal N *et al*. (2012)       Liu K *et al*. (2013)   Wang Y *et al*. (2013)                   Kawaji H *et al*. (2014)                            Xiong Z *et al*. (2015)   Makis W *et al*. (2015)   Peng P *et al*. (2015)                     Chen S *et al*. (2016)                       Chen S *et al*. (2016)
  ----------------------------------------------- ------------------------- ------------------------ --------------------------------------------- ------------------------------ ----------------------- ---------------------------------------- --------------------------------------------------- ------------------------- ------------------------- ------------------------------------------ -------------------------------------------- --------------------------------------------
  Clinical features                                                                                                                                                                                                                                                                                                                                                                                                                                
   Age (years)                                    46                        52                       50                                            50                             40                      23                                       48                                                  56                        64                        56                                         50                                           62
   Sex                                            Female                    Male                     Female                                        Female                         Male                    Female                                   Male                                                NA                        Female                    Male                                       Female                                       Male
   Duration of symptoms (months)                  12                        6                        2                                             NA                             NA                      4                                        3                                                   NA                        NA                        NA                                         2                                            NA
   Initial symptoms                               Visual impairment         Blurred vision           Bitemporal hemianopsia                        Blurred vision in left eye     Visual impairment       Bitemporal visual deficit and headache   Visual impairment                                   NA                        Bitemporal hemianopsia    Bitemporal hemianopsia                     Decreasing vision in left eye and diplopia   Homonymous hemianopsia, temporal both eyes
   Endocrine evaluation                           NA                        NA                       Prolactin 980 mU/L and estradiol \<40 pg/mL   SIADH and prolactin 980 mU/L   NA                      Prolactin 1,003 mU/L, others normal      Mildly elevated prolactin and decreased estradiol   NA                        NA                        Mildly decreased cortisol, others normal   Normal                                       Decreased testosterone and progesterone
  Radiological features                                                                                                                                                                                                                                                                                                                                                                                                                            
   Topography                                     Sellar/suprasellar        Sellar                   Sellar/suprasellar                            Sellar/suprasellar             Sellar/suprasellar      Sellar/suprasellar                       Sellar/suprasellar                                  Suprasellar               Sellar/suprasellar        Sellar/suprasellar                         Sellar/suprasellar                           Sellar/suprasellar
   CT calcification                               Yes                       No                       Yes                                           NA                             No                      No                                       NA                                                  NA                        NA                        NA                                         No                                           NA
   MRI T1                                         Hypo                      Iso                      Iso                                           NA                             Iso                     Iso                                      NA                                                  NA                        NA                        Iso                                        Iso                                          NA
   MRI T2                                         Hyper                     Hyper                    Iso                                           NA                             Iso                     NA                                       NA                                                  NA                        NA                        Hyper                                      Iso                                          NA
   Contrast enhancement                           High                      High                     High                                          NA                             High                    High                                     High                                                NA                        High                      High                                       High                                         High
   Enhancement                                    Heterogeneous             Heterogeneous            Heterogeneous                                 NA                             Heterogeneous           Homogeneous                              Heterogeneous                                       NA                        Heterogeneous             Heterogeneous                              Heterogeneous                                Heterogeneous
   Cystic component                               Present                   Absent                   Present                                       NA                             Present                 Absent                                   Absent                                              NA                        NA                        Absent                                     Present                                      NA
   Cavernous sinus Invasion                       Yes                       NA                       Yes                                           Yes                            Yes                     Yes                                      Yes                                                 NA                        Yes                       Yes                                        Yes                                          Yes
  Pathological and immunohistochemical features                                                                                                                                                                                                                                                                                                                                                                                                    
   Typical/atypical                               Typical                   Typical                  Typical                                       Typical                        Typical                 Typical                                  Atypical                                            Typical                   Atypical                  Typical                                    Typical                                      Typical
   Synaptophysin                                  NA                        Yes                      Yes                                           NA                             NA                      Yes                                      Yes                                                 Yes                       Yes                       Yes                                        Yes                                          Yes
   Neurofilament                                  NA                        NA                       Yes                                           NA                             NA                      Yes                                      Yes                                                 NA                        No                        NA                                         Yes                                          Yes
   NSE                                            Yes                       NA                       No                                            NA                             NA                      NA                                       NA                                                  Yes                       NA                        Yes                                        NA                                           NA
   CgA                                            NA                        Yes                      Yes                                           NA                             NA                      Yes                                      NA                                                  NA                        NA                        Yes                                        NA                                           Yes
   Vimentin                                       Yes                       Yes                      NA                                            NA                             NA                      NA                                       NA                                                  NA                        NA                        NA                                         NA                                           Yes
   NeuN                                           NA                        NA                       NA                                            NA                             NA                      NA                                       Yes                                                 No                        NA                        NA                                         No                                           Yes
   GFAP                                           No                        No                       NA                                            NA                             NA                      No                                       No                                                  No                        NA                        No                                         No                                           No
   Olig2                                          NA                        NA                       NA                                            NA                             NA                      NA                                       NA                                                  No                        NA                        NA                                         NA                                           NA
  Treatment and follow-up                                                                                                                                                                                                                                                                                                                                                                                                                          
   Craniotomy                                     NA                        NA                       No                                            No                             NA                      No                                       Yes                                                 NA                        NA                        Yes                                        Yes                                          Yes
   Endoscopic approach                            NA                        NA                       Yes                                           Yes                            NA                      Yes                                      No                                                  NA                        NA                        No                                         Yes                                          No
   Prior craniotomy                               NA                        No                       No                                            No                             NA                      No                                       No                                                  NA                        NA                        No                                         No                                           No
   Prior endoscopic surgery                       NA                        No                       No                                            No                             NA                      No                                       No                                                  NA                        NA                        No                                         No                                           Yes
   Resection                                      Partial/subtotal          Total                    Partial/subtotal                              Partial/subtotal               NA                      Partial/subtotal                         Partial/subtotal                                    NA                        Partial/subtotal          Total                                      Partial/subtotal                             Partial/subtotal
   Adjuvant radiotherapy                          NA                        No                       Yes                                           Yes                            NA                      Yes                                      Yes                                                 NA                        Yes                       No                                         Yes                                          Yes
   Recurrence                                     No                        NA                       No                                            NA                             NA                      NA                                       Yes                                                 NA                        Yes                       No                                         No                                           No
   Follow-up (months)                             NA                        NA                       18                                            6                              NA                      18                                       6                                                   NA                        NA                        NA                                         36                                           36
   Spinal dissemination                           No                        No                       No                                            No                             No                      No                                       Yes                                                 NA                        No                        No                                         No                                           No

NA=Not available, NSE=Neuron-specific enolase, CgA=Chromogranin A, NeuN=Neuronal nuclear antigen, GFAP=Glial fibrillary acidic protein, SIADH=Syndrome of inappropriate antidiuretic hormone secretion

The reported cases were assessed using CT (66.7%) and/or MRI (100%), which revealed that the tumors were generally solid, bulky (a major axis of ≥3.0 cm), homogeneous, well-defined, and with limited or no swelling in the adjacent parenchyma. Two cases involved small-scattered calcifications, and four cases involved cystic components. All 10 patients with published imaging findings had invasion of the cavernous sinus. The CT scans commonly revealed discreetly iso/hyperdense tumors, and discrete iso/hyperintense findings were observed on approximately 58% of the T1- and T2-weighted images. All reported cases exhibited enhancement after the administration of an iodinated or paramagnetic intravenous contrast agent, with one-half of the results being prominent and nine cases exhibiting heterogeneous enhancement. Ten cases had detailed histological and immunohistochemical data, with generally positive results for synaptophysin expression (9/10 cases) and generally negative results for GFAP expression (8/10 cases). Two patients exhibited signs of malignancy (48 years and 64 years old), with MIB1 indexes of 3% and 4--10%, respectively. Only two patients had gross total tumor resection and eight patients had only partial resection, with 75% of those patients undergoing postoperative radiotherapy. Two patients with atypical extraventricular CN developed distant dural metastases or local recurrences. The main differential diagnosis was pituitary adenoma, especially the nonfunctioning type, which is usually isodense during CT, rarely contains calcification (5--7%) or hemorrhagic foci, and usually exhibits variable hypo/isointense signals during T1- and T2-weighted MRI. Furthermore, pituitary adenoma usually exhibits intense enhancement, but this is slightly slower than the rest of the pituitary gland.\[[@ref3][@ref20]\] Other diagnostic hypotheses include craniopharyngioma (more common in children, heterogeneous lesions, usually contains calcifications)\[[@ref3][@ref19][@ref20]\] and meningiomas (more common in adults, homogeneous lesions, generally isodense during CT and isointense during T1-/T2-weighted MRI, can be calcified).\[[@ref3][@ref19][@ref20]\] In all reported cases, an extraventricular neurocytoma was not suspected based on the preoperative imaging, which strongly indicated a giant pituitary tumor, as in the present case. Therefore, we believe that cases with a suspected huge pituitary lesion should always be screened based on the possibility that it is a sellar/suprasellar neurocytoma. We believe that total tumor resection should be the goal of surgical treatment, and that this goal is achievable using both craniotomy and endoscopic approaches.

In conclusion, we encountered a rare case of an extraventricular CN in the sellar/suprasellar region. Given the unusual nature of this case, we examined the 12 other reported cases and attempted to identify the features and signs that may help facilitate the diagnosis of these tumors in this region. Furthermore, we reported common histopathological characteristics and surgical approaches from those cases. We strongly believe that total tumor resection must be the primary goal of the surgery, and that combined surgical approaches can help facilitate this outcome.
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